These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 29124666)

  • 21. Risk management measures for chemicals in consumer products: documentation, assessment, and communication across the supply chain.
    Bruinen de Bruin Y; Hakkinen PB; Lahaniatis M; Papameletiou D; Del Pozo C; Reina V; Van Engelen J; Heinemeyer G; Viso AC; Rodriguez C; Jantunen M
    J Expo Sci Environ Epidemiol; 2007 Dec; 17 Suppl 1():S55-66. PubMed ID: 17609687
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improving the Safety Assessment of Chemicals and Drug Candidates by the Integration of Bioinformatics and Chemoinformatics Data.
    Steger-Hartmann T; Pognan F
    Basic Clin Pharmacol Toxicol; 2018 Sep; 123 Suppl 5():29-36. PubMed ID: 29316298
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient Registries: An Underused Resource for Medicines Evaluation : Operational proposals for increasing the use of patient registries in regulatory assessments.
    McGettigan P; Alonso Olmo C; Plueschke K; Castillon M; Nogueras Zondag D; Bahri P; Kurz X; Mol PGM
    Drug Saf; 2019 Nov; 42(11):1343-1351. PubMed ID: 31302896
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The implementation of risk minimization measures to prevent teratogenic pregnancy outcomes related to oral retinoid and valproate use in Belgium.
    Bertels X; Mehuys E; Boussery K; Lahousse L
    Acta Clin Belg; 2022 Oct; 77(5):815-822. PubMed ID: 34569444
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Additional Risk Minimisation Measures for Medicinal Products in the European Union: A Review of the Implementation and Effectiveness of Measures in the United Kingdom by One Marketing Authorisation Holder.
    Agyemang E; Bailey L; Talbot J
    Pharmaceut Med; 2017; 31(2):101-112. PubMed ID: 28413313
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regulatory experience of handling Risk Management Plans (RMPs) for medicinal products in the EU.
    Butler D; Vucic K; Straus S; Cupelli A; Micallef B; Serracino-Inglott A; Borg JJ
    Expert Opin Drug Saf; 2021 Jul; 20(7):815-826. PubMed ID: 33843379
    [No Abstract]   [Full Text] [Related]  

  • 28. Are drug safety measures harmonized? A real-world evidence from three regulatory authorities.
    Alelayan S; Al-Sheikh L; Almotawa R; Alkofide H; Alshammari T
    Saudi Pharm J; 2024 Mar; 32(3):101963. PubMed ID: 38328792
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How has the impact of 'care pathway technologies' on service integration in stroke care been measured and what is the strength of the evidence to support their effectiveness in this respect?
    Allen D; Rixson L
    Int J Evid Based Healthc; 2008 Mar; 6(1):78-110. PubMed ID: 21631815
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The utility of real-world evidence for benefit-risk assessment, communication, and evaluation of pharmaceuticals: Case studies.
    Radawski CA; Hammad TA; Colilla S; Coplan P; Hornbuckle K; Freeman E; Smith MY; Sobel RE; Bahri P; Arias AE; Bennett D
    Pharmacoepidemiol Drug Saf; 2020 Dec; 29(12):1532-1539. PubMed ID: 33146901
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of real-world evidence in postmarketing medicines regulation in the European Union: a systematic assessment of European Medicines Agency referrals 2013-2017.
    Brown JP; Wing K; Evans SJ; Bhaskaran K; Smeeth L; Douglas IJ
    BMJ Open; 2019 Oct; 9(10):e028133. PubMed ID: 31662354
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
    Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
    Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluating the Safety Profile of Non-Active Implantable Medical Devices Compared with Medicines.
    Pane J; Coloma PM; Verhamme KM; Sturkenboom MC; Rebollo I
    Drug Saf; 2017 Jan; 40(1):37-47. PubMed ID: 27928726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The reorganisation of European pharmacovigilance. Part 2. From spontaneous reports to agency reviews and decisions.
    Prescrire Int; 2015 Feb; 24(157):50-4. PubMed ID: 25802924
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulatory review time and post-market safety events for novel medicines approved by the EMA between 2001 and 2010: a cross-sectional study.
    Zeitoun JD; Lefèvre JH; Downing NS; Bergeron H; Ross JS
    Br J Clin Pharmacol; 2015 Oct; 80(4):716-26. PubMed ID: 25808713
    [TBL] [Abstract][Full Text] [Related]  

  • 37. From molecule to market access: drug regulatory science as an upcoming discipline.
    Gispen-de Wied CC; Leufkens HGM
    Eur J Pharmacol; 2013 Nov; 719(1-3):9-15. PubMed ID: 23891846
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Reporting Recommendations Intended for Pharmaceutical Risk Minimization Evaluation Studies: Standards for Reporting of Implementation Studies Extension (RIMES-SE).
    Smith MY; Morrato EH; Mora N; Nguyen V; Pinnock H; Winterstein AG
    Drug Saf; 2024 Jul; 47(7):655-671. PubMed ID: 38478350
    [TBL] [Abstract][Full Text] [Related]  

  • 39. European pharmacovigilance: increasingly outsourced to drug companies.
    Prescrire Int; 2014 Dec; 23(155):302-3, 305-7. PubMed ID: 25629153
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Scientific advice by the nationally competent authority and by the EMEA on the conduct of clinical trials].
    Dejas-Eckertz P; Schäffner G
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Apr; 48(4):423-8. PubMed ID: 15830253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.